# A Clinical Study of TQB3107 Tablets in Patients With Malignant Tumors

> **NCT06413953** · PHASE1 · RECRUITING · sponsor: **Chia Tai Tianqing Pharmaceutical Group Co., Ltd.** · enrollment: 140 (estimated)

## Conditions studied

- Advanced Cancers

## Interventions

- **DRUG:** TQB3107 Tablets

## Key facts

- **NCT ID:** NCT06413953
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-06-27
- **Primary completion:** 2025-06
- **Final completion:** 2026-12
- **Target enrollment:** 140 (ESTIMATED)
- **Last updated:** 2024-07-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06413953

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06413953, "A Clinical Study of TQB3107 Tablets in Patients With Malignant Tumors". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06413953. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*